Chronic Kidney Disease Epidemiology Analysis and Forecast, 2021-2031

Chronic kidney disease (CKD) (ICD-10 = N18) is a condition characterized by a gradual loss of kidney function over time. This leads to the accumulation of excess fluid and waste in the body. In the early stages, CKD is a largely asymptomatic condition. As the disease progresses, the symptoms worsen and eventually lead to kidney failure (Centers for Disease Control and Prevention, 2022). Advanced chronic kidney disease can cause dangerous levels of fluid, electrolytes, and wastes to build up in the body (Mayo Clinic, 2021). The glomerular filtration rate (GFR), a key measure of kidney function, is determined by the amount of creatinine in the blood, and the Kidney Disease Improving Global Outcomes (KDIGO) classification system is considered to be the standard for GFR measurement and diagnosis of CKD (Levin et al., 2013). This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CKD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

The report includes a 10-year epidemiology forecast for the total prevalent cases and diagnosed prevalent cases of CKD. The total and diagnosed prevalent cases of CKD are further segmented by age (18 years and older), sex, and stage (stage I, stage II, stage IIIa, stage IIIb, stage IV, and stage V) in these markets. Diagnosed prevalent cases of CKD are further segmented by dialysis-dependent (including both hemodialysis and peritoneal dialysis) and non-dialysis dependent. The following data describes epidemiology of CKD. In the 7MM, GlobalData epidemiologists forecast an increase in the total prevalent cases of CKD from 103,485,844 cases of CKD in 2021 to 114,351,930 cases of CKD in 2031, with an AGR of 1.05% during the forecast period. The diagnosed prevalent cases of CKD in the 7MM are expected to increase from 18,135,434 cases in 2021 to 19,917,590 cases in 2030, with an AGR of 0.98% during the forecast period. Women accounted for more total and diagnosed prevalent cases of CKD than men in the 7MM and it predominantly affects older adults. These findings are in line with the GlobalData estimates and these trends are reflected in GlobalData's forecast for the total and diagnosed prevalent cases for the 7MM.

Scope

• The Chronic Kidney Disease (CKD) Epidemiology Report provides an overview of the risk factors and global trends of CKD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report includes a 10-year epidemiological forecast for the total and diagnosed prevalent cases of CKD. The total and diagnosed prevalent cases of CKD are further segmented by age (18 years and older), sex, and stage (stage I, stage II, stage IIIa, stage IIIb, stage IV, and stage V) in these markets. Diagnosed prevalent cases of CKD are further segmented by dialysis-dependent (including both hemodialysis and peritoneal dialysis) and non-dialysis dependent. The model associated with the report also provides the diagnosed prevalent cases of CKD further segmented by hyperparathyroidism, hyperphosphatemia, and hyperkalemia among dialysis-dependent and non-dialysis-dependent cases.
• The CKD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

The Chronic Kidney Disease (CKD) Epidemiology series will allow you to -

• Develop business strategies by understanding the trends shaping and driving the global CKD market.
• Quantify patient populations in the global CKD market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CKD therapeutics in each of the markets covered.
• Understand magnitude of CKD population by subtype, digital vasculopathy, and other internal organ involvement.